Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Akebia Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 114
- +27 vs. Q4 2023
- Shares held
- 57.0M
- +2.28M (+4.2%) vs. Q4 2023
- Total value
- $104.3M
- +$31.7M (+43.6%) vs. Q4 2023
- New holders
- 40
- 27 more added
- Sold out
- 13
- 24 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AKBA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 170 | $123.2M |
| Q1 2026 | 171 | $141.4M |
| Q4 2025 | 166 | $190.4M |
| Q3 2025 | 177 | $337.7M |
| Q2 2025 | 158 | $394.1M |
| Q1 2025 | 143 | $182.7M |
| Q4 2024 | 121 | $128.9M |
| Q3 2024 | 114 | $78.4M |
| Q2 2024 | 103 | $57.4M |
| Q1 2024 | 114 | $104.3M |
| Q4 2023 | 87 | $72.7M |
| Q3 2023 | 76 | $58.0M |
| Q2 2023 | 79 | $46.0M |
| Q1 2023 | 65 | $29.1M |
| Q4 2022 | 75 | $30.2M |
| Q3 2022 | 90 | $16.5M |
| Q2 2022 | 97 | $20.2M |
| Q1 2022 | 124 | $58.3M |
| Q4 2021 | 133 | $218.7M |
| Q3 2021 | 127 | $283.7M |
| Q2 2021 | 139 | $402.4M |
| Q1 2021 | 145 | $340.3M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Akebia Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CWM, LLC | 1,000 | $2.00K | 0.00% | +1,000 | New |
| Guggenheim Capital LLC | 1,039 | $1.90K | 0.00% | +1,039 | New |
| Truvestments Capital LLC | 756 | $1.38K | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 748 | $1.37K | 0.00% | 00.0% | Unchanged |
| Baldwin Brothers Inc | 561 | $1.03K | 0.00% | 00.0% | Unchanged |
| Capital Advisors, Ltd. LLC | 320 | $1.00K | 0.00% | 00.0% | Unchanged |
| NBC Securities, Inc. | 690 | $1.00K | 0.00% | +690 | New |
| JPMorgan Chase & Co | 231 | $423 | 0.00% | 00.0% | Unchanged |
| Hexagon Capital Partners LLC | 186 | $340 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 171 | $313 | 0.00% | −8,677−98.1% | Reduced |
| Federation des caisses Desjardins du Quebec | 150 | $275 | 0.00% | 00.0% | Unchanged |
| CIBC Private Wealth Group, LLC | 100 | $163 | 0.00% | +100 | New |
| Macquarie Group Ltd | 9,170 | $17 | 0.00% | +9,170 | New |
| Royal Bank of Canada | 238 | $0 | 0.00% | +138+138.0% | Added |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −185,399−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −99,645−100.0% | Sold out |
| Mirabella Financial Services LLP | 0 | $0 | 0.00% | −65,300−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −65,083−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −59,479−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −39,725−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,550−100.0% | Sold out |
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −20,235−100.0% | Sold out |
| Archer Investment Corp | 0 | $0 | 0.00% | −19,800−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −15,094−100.0% | Sold out |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Johnson Financial Group, Inc. | 0 | $0 | 0.00% | −1,400−100.0% | Sold out |
| Focused Wealth Management, Inc | 0 | $0 | 0.00% | −65−100.0% | Sold out |